3Braendle W,Kuhl H,Mueek A,el al.Does hormonal contraception increase the rish for tumors?[J].Ther Umsch,2009,66(2):129-135.
4Ge Qs,Tian QJ,Tseng H,et al.Development of low-dose reproductive hormone therapies in China[J].Cynecol Endocrinol,2006,22(11):636-645.
5Kauatiz AM,Miller PD,Rice VM,et al.Bone mineral density in women aged 25-35 years receiving depol medroxyprogesterone acetate; Recovery following discontinuation[J].Contraception,2006,74(2):90-99.
6Albertazzi P,Botazzi M,Steel SA.Bone mineral density and depot medroxyprogesterone acetate[J].Contraception,2006,73(6):577-583.
7Tao MH,Xu WH,Zheng W,et al.Oral contraception and IUD use and endometrial cancer; a population-based case-control study in shanghai,China[J].Int J Cancer,2006,119(9):2142-2147.
8Kahlenbom C,Modugon F,Potter DM,et al.Oral contractive use as a rise factor for premenopausal breast cancer:a meta-analysia[J].Mayo Clin Proe,2006,81(10):1290-1320.
9Haile RW,Thomas DC,McGuire V,et al.BRCAL and BRCA2 mutation carriers,oral contractive use,and breast cancer before age 50[J].Cancer Epidemiol Biomakers Prev,2006,15(10):1863-1870.
10Vessey P,Painter R.Oral contraception use and cancer.Findings in a large cohort study[J].Br J Cancer,2006,95(3):385-389.
